9-allyl-6-allylamino-2-{4-[(2,2-diphenylethyl)amino]piperidino}purine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 9-allyl-6-allylamino-2-{4-[(2,2-diphenylethyl)amino]piperidino}purine
• 英文别名: Allyl-{9-allyl-2-[4-(2,2-diphenyl-ethylamino)-piperidin-1-yl]-9H-purin-6-yl}-amine；2-[4-(2,2-diphenylethylamino)piperidin-1-yl]-N,9-bis(prop-2-enyl)purin-6-amine
• 化学式: C₃₀H₃₅N₇
• 分子量: 493.655
• InChiKey: ASHVAPGYJMVLMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  37
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  70.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,6-二氯嘌呤 在 盐酸 、 三乙酰氧基硼氢化钠 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 12.5h， 生成 9-allyl-6-allylamino-2-{4-[(2,2-diphenylethyl)amino]piperidino}purine
  参考文献：
  名称：

  New Purines and Purine Analogs as Modulators of Multidrug Resistance

  摘要：

  A series of 36 purine and purine analog derivatives have been synthesized and tested for their ability to modulate multidrug resistance in vitro (P388/VCR-20 and KB-A1 cells) and in vivo (P388/VCR leukemia). Compounds were compared to S9788, a triazine derivative which has already shown some activity during phase 1 clinical trials and also a limiting cardiovascular side effect possibly linked to its calcium channel affinity. The fact that active compounds increase adriamycin accumulation in the resistant KB-A1 cells, and not in the sensitive KB-3-1 cells, suggests they act predominantly by inhibiting the P-glycoprotein-catalyzed efflux of cytotoxic agents. No direct relation was found between the affinity for the phenylalkylamine binding site of the calcium channel and in vitro sensitization of resistant cells. In vivo, when administered po in association with vincristine (0.25 mg/kg), five compounds (3, 4, 9, 25, and 26), of very differing calcium channel affinities (K-i from 5 to 560 nM), fully restored (T/V greater than or equal to 1.4) the sensitivity of P388/VCR leukemia to vincristine.

  DOI：

  10.1021/jm960361i

文献信息

• COMPOSES BICYCLIQUES DE PYRIMIDINE, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES RENFERMANT
  申请人：ADIR ET COMPAGNIE

  公开号：EP0673376B1

  公开（公告）日：1996-05-22
• US5508277A
  申请人：——

  公开号：US5508277A

  公开（公告）日：1996-04-16
• New Purines and Purine Analogs as Modulators of Multidrug Resistance
  作者：Alain Dhainaut、Gilbert Regnier、Andre Tizot、Alain Pierre、Stephane Leonce、Nicolas Guilbaud、Laurence Kraus-Berthier、Ghanem Atassi

  DOI：10.1021/jm960361i

  日期：1996.1.1

  A series of 36 purine and purine analog derivatives have been synthesized and tested for their ability to modulate multidrug resistance in vitro (P388/VCR-20 and KB-A1 cells) and in vivo (P388/VCR leukemia). Compounds were compared to S9788, a triazine derivative which has already shown some activity during phase 1 clinical trials and also a limiting cardiovascular side effect possibly linked to its calcium channel affinity. The fact that active compounds increase adriamycin accumulation in the resistant KB-A1 cells, and not in the sensitive KB-3-1 cells, suggests they act predominantly by inhibiting the P-glycoprotein-catalyzed efflux of cytotoxic agents. No direct relation was found between the affinity for the phenylalkylamine binding site of the calcium channel and in vitro sensitization of resistant cells. In vivo, when administered po in association with vincristine (0.25 mg/kg), five compounds (3, 4, 9, 25, and 26), of very differing calcium channel affinities (K-i from 5 to 560 nM), fully restored (T/V greater than or equal to 1.4) the sensitivity of P388/VCR leukemia to vincristine.